自间变性大细胞淋巴瘤（ALCL）中首次发现间变性淋巴瘤激酶（ALK）以来，ALK阳性肿瘤谱系已显著拓宽，从最初的淋巴瘤扩展至非小细胞肺癌（NSCLC）、甲状腺癌等多种实体瘤[1]。ALK的激活机制复杂多样，包括基因重排、基因扩增以及点突变[1]，其中，点突变多见于甲状腺未分化癌中[2]。目前，针对ALK靶点的药物种类较多，其中酪氨酸激酶抑制剂（TKI）通过精准抑制ALK活性，展现了显著的临床疗效。为进一步探索ALK阳性肿瘤患者的治疗效果，中国医学论坛报社开展“实例呈现——最佳临床病例分享项目”。
第六期特邀福建省肿瘤医院吴宇教授分享《一例ALK阳性晚期甲状腺癌患者后线接受伊鲁阿克治疗PFS超8个月》，并邀请福建省肿瘤医院刘辉教授进行点评。现将病例及点评内容整理如下，供大家分享、交流。
参考文献：
[1] Minoo P, Wang HY. ALK-immunoreactive neoplasms. Int J Clin Exp Pathol. 2012;5(5):397-410.
[2] Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 2011;71:4403–4411.
[3] Shi Y, Chen J, Yang R, et al. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). J Thorac Oncol. 2024 Jun;19(6):912-927.
[4] Shreenivas A, Janku F, Gouda MA, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023 Sep 29;7(1):101.
[5] Shibata M, Shen MM. The roots of cancer: stem cells and the basis for tumor heterogeneity. Bioessays. 2013 Mar;35(3):253-60.
[6] Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 2023 Feb 24;21(1):72.
[7] Shi Y, Fang J, Hao X,et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022 Jan 28;7(1):25.
[8] Zhang Q, Lv J, Li X,et al. Efficacy and safety of iruplinalkib (WX0593) on nonsmall cell lung cancer with SPECC1LALK fusion: A case report. Exp Ther Med. 2023 Dec 5;27(2):53.
[9] Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014 Oct 23;159(3):676-90.
[10] Ji JH, Oh YL, Hong M,et al. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genet. 2015 Aug 21;11(8):e1005467.
